论文部分内容阅读
目的比较头孢哌酮舒巴坦钠与头孢他啶治疗慢性支气管炎革兰阴性菌感染的临床疗效,为治疗革兰阴性菌感染提供临床依据。方法将革兰阴性菌感染的慢性支气管炎患者96例随机分为2组各48例,观察组给予头孢哌酮舒巴坦钠治疗,对照组给予头孢他啶治疗,2组疗程均为15 d,比较2组临床疗效、细菌清除率及不良反应发生情况。结果观察组总有效率及细菌清除率均明显高于对照组,不良反应发生率明显低于对照组,差异均有统计学意义(P<0.05)。结论头孢哌酮舒巴坦钠治疗慢性支气管炎革兰阴性菌感染有较好的临床疗效,细菌清除率高,且不良反应发生率低,值得临床推广使用。
Objective To compare the clinical efficacy of cefoperazone and sulbactam sodium and ceftazidime in the treatment of gram-negative bacterial infections of chronic bronchitis, and to provide a clinical basis for the treatment of Gram-negative bacterial infections. Methods Ninety-six chronic bronchitis patients infected with Gram-negative bacteria were randomly divided into two groups (n = 48). The observation group was treated with cefoperazone sulbactam sodium and the control group was treated with ceftazidime. The course of treatment was 15 days in both groups Two groups of clinical efficacy, bacterial clearance and adverse reactions occurred. Results The total effective rate and bacterial clearance rate in the observation group were significantly higher than those in the control group, and the incidence of adverse reactions was significantly lower than that in the control group (P <0.05). Conclusion Cefoperazone sulbactam sodium has good clinical efficacy in the treatment of gram-negative bacterial infections of chronic bronchitis. The bacterial clearance rate is high and the incidence of adverse reactions is low, which is worthy of clinical promotion.